Dysfunctional HDLs are Associated with a Greater Incidence of Acute Coronary Syndrome in a Population at High Cardiovascular Risk: A Nested-Case Control Study.

Background: Studies have failed to establish a clear link between high-density lipoprotein (HDL) cholesterol and cardiovascular disease, leading to the hypothesis that HDL atheroprotective role lies in its biological activity rather than in its cholesterol content. However, to date, the association between HDL functional characteristics and acute coronary syndrome has not been comprehensively investigated. Methods: We conducted a case-control study nested within the PREDIMED (Prevención con Dieta Mediterránea) cohort, originally a randomized trial where participants followed a Mediterranean or low-fat diet. Incident acute coronary syndrome cases (N=167) were individually matched (1:2) to controls by sex, age, intervention group, body mass index, and follow-up time. We investigated its two individual manifestations (myocardial infarction, unstable angina) as secondary outcomes. We measured the following functional characteristics: HDL cholesterol concentration (in plasma); cholesterol efflux capacity; antioxidant ability measured by the HDL oxidative-inflammatory index; phospholipase A2 activity; and sphingosine-1-phosphate, apolipoproteins A-I and A-IV, serum amyloid A, and complement 3 protein (in apolipoprotein B-depleted plasma). We used conditional logistic regression models adjusted for HDL cholesterol levels and cardiovascular risk factors to estimate odds ratios (ORs) between one standard deviation increments in HDL functional characteristics and clinical outcomes. Results: Low values of cholesterol efflux capacity (OR1SD: 0.58, 95% CI: 0.40-0.83), and levels of sphingosine-1-phosphate (OR1SD: 0.70, 95% CI: 0.52-0.92), and apolipoprotein A-I (OR1SD: 0.58, 95% CI: 0.42-0.79) were associated with higher odds of acute coronary syndrome. Higher HDL oxidative inflammatory index values were marginally linked to acute coronary syndrome risk (OR1SD: 1.27, 95% CI: 0.99-1.63). Low values of cholesterol efflux capacity (OR1SD: 0.33, 95% CI: 0.18-0.61), sphingosine-1-phosphate (OR1SD: 0.60, 95% CI: 0.40-0.89) and apolipoprotein A-I (OR1SD: 0.59, 95% CI: 0.37-0.93) were particularly linked to myocardial infarction, whereas high HDL oxidative-inflammatory index values (OR1SD: 1.53, 95% CI: 1.01-2.33) and low apolipoprotein A-I levels (OR1SD: 0.52, 95% CI: 0.31-0.88) were associated with unstable angina. Conclusions: Low cholesterol efflux capacity values, pro-oxidant/pro-inflammatory HDL particles, and low HDL levels of sphingosine-1-phosphate and apolipoprotein A-I were associated with increased odds of acute coronary syndrome and its manifestations in high cardiovascular risk subjects. Clinical Trial Registration: URL: http://www.controlled-trials.com Unique identifier: ISRCTN35739639.

[1]  D. Corella,et al.  Association Between Fatty Acids of Blood Cell Membranes and Incidence of Coronary Heart Disease: A Case-Control Study Nested in the PREDIMED Trial , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[2]  A. Tall,et al.  Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[3]  P. Joshi,et al.  Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events. , 2018, Journal of the American College of Cardiology.

[4]  J. Martínez,et al.  Retraction and Republication: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013;368:1279-90. , 2018, The New England journal of medicine.

[5]  P. Whelton,et al.  Response by Beddhu et al to Letters Regarding Article, "Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control". , 2018, Circulation.

[6]  Quan Zhou,et al.  High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis , 2017, Lipids in Health and Disease.

[7]  C. Wanner,et al.  HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients. , 2017, Journal of the American Society of Nephrology : JASN.

[8]  D. Fliser,et al.  HDL Cholesterol Efflux Capacity and Cardiovascular Events in Patients With Chronic Kidney Disease. , 2017, Journal of the American College of Cardiology.

[9]  Y. Zhang,et al.  Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: A prospective cohort study. , 2016, Atherosclerosis.

[10]  Changhao Wu,et al.  Prognostic Usefulness of Serum Cholesterol Efflux Capacity in Patients With Coronary Artery Disease. , 2016, The American journal of cardiology.

[11]  S. Bakker,et al.  Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. , 2016, Atherosclerosis.

[12]  J. Heinecke,et al.  Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL , 2015, Current opinion in lipidology.

[13]  R. Erbel,et al.  Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphingosine-1-Phosphate Content: Correction by Sphingosine-1-Phosphate-Loading. , 2015, Journal of the American College of Cardiology.

[14]  D. Rader,et al.  Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study , 2015, The lancet. Diabetes & endocrinology.

[15]  B. Kleuser,et al.  The role of serum amyloid A and sphingosine-1-phosphate on high-density lipoprotein functionality , 2015, Biological chemistry.

[16]  A. Khera,et al.  HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.

[17]  A. Tselepis,et al.  Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A₂ (Lp-PLA₂) bound to LDL and HDL. , 2014, Current pharmaceutical design.

[18]  Solid-Timi Investigators Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. , 2014 .

[19]  Darrel P Francis,et al.  Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients , 2014, BMJ : British Medical Journal.

[20]  R. Erbel,et al.  HDL-Bound Sphingosine 1-Phosphate (S1P) Predicts the Severity of Coronary Artery Atherosclerosis , 2014, Cellular Physiology and Biochemistry.

[21]  P. Pais,et al.  Darapladib for preventing ischemic events in stable coronary heart disease. , 2014, The New England journal of medicine.

[22]  A. Khera,et al.  Anti‐oxidative and cholesterol efflux capacities of high‐density lipoprotein are reduced in ischaemic cardiomyopathy , 2013, European journal of heart failure.

[23]  P. Barter,et al.  Translation of High-Density Lipoprotein Function Into Clinical Practice: Current Prospects and Future Challenges , 2013, Circulation.

[24]  S. Hazen,et al.  Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[25]  J. Lekakis,et al.  Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. , 2012, Journal of the American College of Cardiology.

[26]  H. Berrougui,et al.  Health benefits of high-density lipoproteins in preventing cardiovascular diseases. , 2012, Journal of clinical lipidology.

[27]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[28]  Zahi A Fayad,et al.  Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. , 2012, Circulation.

[29]  Dolores Corella,et al.  Cohort profile: design and methods of the PREDIMED study. , 2012, International journal of epidemiology.

[30]  T. Lüscher,et al.  Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease , 2012, EMBO molecular medicine.

[31]  Swneke D. Bailey,et al.  The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. , 2012, Biochimica et biophysica acta.

[32]  R. Bittman,et al.  A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol , 2011, Journal of Lipid Research.

[33]  P. Giral,et al.  Stimulation of Cholesterol Efflux by LXR Agonists in Cholesterol-Loaded Human Macrophages Is ABCA1-Dependent but ABCG1-Independent , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[34]  A. Kontush,et al.  Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.

[35]  G. Norata,et al.  Modified HDL: biological and physiopathological consequences. , 2006, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[36]  G. Lewis,et al.  HDL metabolism in hypertriglyceridemic states: an overview. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[37]  A E Becker,et al.  Atherosclerotic plaque rupture--pathologic basis of plaque stability and instability. , 1999, Cardiovascular research.

[38]  R. Stocker,et al.  Oxidation of High Density Lipoproteins , 1998, The Journal of Biological Chemistry.

[39]  A G Babiker,et al.  Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. , 1991, Statistics in medicine.

[40]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[41]  P. Barter,et al.  Dysfunctional HDL and atherosclerotic cardiovascular disease , 2016, Nature Reviews Cardiology.

[42]  Dylan L. Steen,et al.  Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. , 2014, JAMA.

[43]  Edinburgh Research Explorer Mendelian randomization of blood lipids for coronary heart disease , 2022 .